Latest / Markets & Money News Today | 2 Min News | THE DAILY NOW!
Cumberland Pharma Stock Falls 11% After Trial | Markets & Money News
Cumberland Pharmaceuticals faces a setback as its stock dropped 11% following disappointing results from the Phase 2a ASSIST-SSc trial of oral ifetroban for systemic sclerosis patients. Although the medication showed tolerance among participants, it did not demonstrate significant effectiveness, complicating treatment comparisons. Increased gastrointestinal side effects were noted, along with a rise in bleeding-related adverse events. Cumberland plans to submit a clinical study report to the
www.TheDailyNewsNow.com
This is an automated, high-level news summary based on public reporting and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.